ARRIVENT BIOPHARMA INC

AVBPNASDAQ

🏆 #1968 by market capUS Equity

$31.25▼ $0.14 (−0.45%)

Live

1h▼ 0.1%

24h▼ 0.5%

7d▲ 2.3%

14d▲ 4.1%

30d▼ 7.2%

1y▲ 84.5%

🏦Market Cap

$1.46B

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $31.04 – $31.46
52-Week Range: $16.10 – $35.83
Volume: $3.30B
Avg Volume: $2.87B
Shares Outstanding: 46.6M
Next Earnings: Oct 18, 2026

Fundamentals Snapshot

Annual Revenue: $92M
Last Q Revenue: $22M
P/E Ratio: -8.9
P/S Ratio: 0.0x
EPS (TTM): $-3.22
Dividend Yield: 0.00%

Why Investors Own AVBP

✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
✓Healthy economics — 67% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$92M▲ +35.8% YoY

Gross Margin (TTM)

66.8%▲ +0.6% YoY

Operating Income (TTM)

$12M▲ +35.8% YoY

Free Cash Flow (TTM)

$10M▲ +35.8% YoY

About ARRIVENT BIOPHARMA INC

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

🦦